National Stroke Foundation


The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Approval Status:

Approved July 1997

Specific Treatments:

acute pain

General Information

Bromfenac was cleared for marketing by the FDA on July 15, 1997. This provides an alternative to opioids for the management of acute pain. Bromfenac provides fast relief of acute pain without the side effects of opioid analgesics.

Side Effects

Possible adverse side effects include abdominal pain, headache, nausea, and vomiting.